SOGROYA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novo Nordisk. The primary component is Somapacitan.
| Product ID | 0169-2030_6c3b1f43-a9c6-445d-b82a-bbf2223857d6 |
| NDC | 0169-2030 |
| Product Type | Human Prescription Drug |
| Proprietary Name | SOGROYA |
| Generic Name | Somapacitan-beco |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2021-06-15 |
| Marketing Category | BLA / |
| Application Number | BLA761156 |
| Labeler Name | Novo Nordisk |
| Substance Name | SOMAPACITAN |
| Active Ingredient Strength | 7 mg/mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2021-06-15 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0169-2030 | SOGROYA | somapacitan-beco |
| 0169-2035 | SOGROYA | somapacitan-beco |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() SOGROYA 79262550 5934737 Live/Registered |
Novo Nordisk Health Care AG 2019-05-24 |